Human gamma delta T cells are unique innate immune cells which contribute to about 1%-5% of the lymphocytes in the peripheral blood.
“Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Adopted Approaches for Gamma Delta T Cell Therapy
Download Report:
https://www.kuickresearch.com/report-gamma-delta-t-cells-therapy-market
Human gamma delta T cells are unique innate immune cells which contribute to about 1%-5% of the lymphocytes in the peripheral blood. These cells are mainly distributed in gut mucosa, skin and other mucosal tissues and have critical role in immune response and immune regulation process, such as mediating immune inflammatory response, directly recognizing and killing tumors. In recent times, gamma delta T cells have gained momentum in the field of therapeutics because they can quickly generate immune response to a variety of pathogens and early chances of malignancy.
The therapeutic potential of these molecules in the management of cancer has prompted the researchers to develop novel immunotherapy molecules utilizing these molecules. Currently, scientists have utilized two approaches to utilize the therapeutic potential of gamma delta T cells including bispecific antibodies and chimeric antigen receptor (CAR) T-cells. The novel gamma delta T cell therapy is mainly confined to early stages of clinical trials and preclinical studies, but has demonstrated encouraging response which has surged the investment in this sector. Several pharmaceutical companies including Lava Therapeutics, In8Bio, Gamma Delta Therapeutics, Cytomed Therapeutics, Kiromic Biopharma, Adicet, and others have developed a robust clinical pipeline of gamma delta T cell therapy products which are expected to enter the market in forthcoming years.
INB-100, a donor-derived gamma-delta T cell therapeutic developed by In8Bio is currently present in phase-I clinical trial in patients with leukemia undergoing haploidentical hematopoietic stem cell transplant (HSCT). The results from the trial demonstrated that the investigational gamma delta T cell therapy has manageable profile. Apart from this, LAVA-1207 developed by Lava Therapeutics has also shown promising preclinical activity in the management of prostate cancer. The encouraging preclinical response has led to translation into clinical trials, which further boosts the growth of market.
Apart from this, several gamma delta T cell therapy products also entered the phase-I clinical trial recently. For instance in 2021, Gamma Delta Therapeutics initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood and was also granted orphan drug designation by US FDA. Furthermore, Century Therapeutics and Bristol Myers Squibb also entered into strategic collaboration to develop novel gamma delta T cell therapies. The increasing investment among the pharmaceutical companies suggests the promising future of gamma delta T cells in the management of cancer.
As per our report findings, the global gamma delta T cell therapy market is expected to surpass US$ 4 Billion by 2028. In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the presence of strong clinical pipeline of products and their positive clinical response justifies that in next 5-7 years market will be flourished with potential drug candidates which have the ability to combat a wide range of cancers. Further, the exploitation of the therapy in management of other diseases including HIV, and other viral infections will also propel the growth of market.
The report provides insights on key drugs in research and development and ongoing clinical trials. The report also analyzes the role of gamma delta T cells in various cancers and future market opportunity till 2028. In addition, various players in the market and the ongoing business trends in the market are also include in the report. On the basis of indication, the market is segmented into breast cancer, prostate cancer, leukemia, lung cancer, neuroblastoma, and colorectal cancer.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366